 Irina Alimova
Concepts (208)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rhabdoid Tumor | 5 | 2022 | 80 | 1.910 |
Why?
| | Medulloblastoma | 10 | 2022 | 172 | 1.670 |
Why?
| | Radiation Tolerance | 5 | 2022 | 92 | 1.440 |
Why?
| | Teratoma | 4 | 2022 | 92 | 1.280 |
Why?
| | Cerebellar Neoplasms | 7 | 2022 | 131 | 1.040 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2019 | 312 | 0.890 |
Why?
| | Cell Proliferation | 14 | 2022 | 2199 | 0.790 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 1 | 2022 | 56 | 0.780 |
Why?
| | Cell Cycle Proteins | 6 | 2022 | 552 | 0.740 |
Why?
| | Gene Expression Regulation, Neoplastic | 7 | 2019 | 1148 | 0.730 |
Why?
| | Proto-Oncogene Proteins c-myc | 2 | 2019 | 115 | 0.710 |
Why?
| | Apoptosis | 13 | 2022 | 2371 | 0.670 |
Why?
| | Cell Cycle | 9 | 2016 | 544 | 0.650 |
Why?
| | SMARCB1 Protein | 1 | 2019 | 17 | 0.650 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2022 | 447 | 0.610 |
Why?
| | Cellular Senescence | 3 | 2019 | 153 | 0.610 |
Why?
| | Molecular Targeted Therapy | 2 | 2016 | 347 | 0.540 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2016 | 399 | 0.520 |
Why?
| | Polycomb Repressive Complex 2 | 2 | 2012 | 59 | 0.490 |
Why?
| | Cell Line, Tumor | 13 | 2022 | 2725 | 0.460 |
Why?
| | RNA, Small Interfering | 2 | 2012 | 543 | 0.440 |
Why?
| | Neoplastic Stem Cells | 2 | 2014 | 334 | 0.410 |
Why?
| | Biomarkers, Tumor | 3 | 2016 | 1054 | 0.380 |
Why?
| | Metformin | 2 | 2009 | 278 | 0.320 |
Why?
| | Transcription Factors | 2 | 2014 | 1530 | 0.300 |
Why?
| | Proto-Oncogene Proteins | 4 | 2022 | 611 | 0.290 |
Why?
| | Cerebellum | 3 | 2012 | 200 | 0.270 |
Why?
| | DNA-Binding Proteins | 1 | 2012 | 1317 | 0.250 |
Why?
| | Blotting, Western | 6 | 2014 | 1151 | 0.250 |
Why?
| | Tumor Cells, Cultured | 5 | 2014 | 855 | 0.250 |
Why?
| | Nuclear Proteins | 3 | 2014 | 593 | 0.230 |
Why?
| | Radiation-Sensitizing Agents | 2 | 2016 | 38 | 0.230 |
Why?
| | Azepines | 3 | 2019 | 74 | 0.210 |
Why?
| | Enhancer of Zeste Homolog 2 Protein | 2 | 2012 | 37 | 0.210 |
Why?
| | Spheroids, Cellular | 2 | 2012 | 58 | 0.200 |
Why?
| | Pyrazoles | 4 | 2022 | 364 | 0.200 |
Why?
| | Polycomb Repressive Complex 1 | 2 | 2020 | 40 | 0.200 |
Why?
| | Aging | 4 | 2020 | 1621 | 0.190 |
Why?
| | Hypoglycemic Agents | 1 | 2009 | 1008 | 0.190 |
Why?
| | Mice, Nude | 3 | 2019 | 635 | 0.190 |
Why?
| | Breast Neoplasms | 2 | 2009 | 1870 | 0.180 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2019 | 706 | 0.180 |
Why?
| | Triazoles | 2 | 2019 | 130 | 0.170 |
Why?
| | Receptor, ErbB-2 | 4 | 2009 | 301 | 0.170 |
Why?
| | Quinazolines | 2 | 2022 | 243 | 0.170 |
Why?
| | Oligonucleotide Array Sequence Analysis | 4 | 2016 | 744 | 0.160 |
Why?
| | Pteridines | 2 | 2016 | 20 | 0.160 |
Why?
| | Chromatin | 2 | 2020 | 428 | 0.160 |
Why?
| | Mammary Neoplasms, Animal | 3 | 2003 | 28 | 0.160 |
Why?
| | RNA, Messenger | 5 | 2014 | 2558 | 0.160 |
Why?
| | Cell Self Renewal | 1 | 2019 | 49 | 0.160 |
Why?
| | Cell Differentiation | 4 | 2020 | 1699 | 0.160 |
Why?
| | Antineoplastic Agents | 4 | 2022 | 1897 | 0.160 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2019 | 132 | 0.150 |
Why?
| | Real-Time Polymerase Chain Reaction | 3 | 2014 | 316 | 0.150 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 4 | 2014 | 929 | 0.140 |
Why?
| | Glioma | 2 | 2020 | 296 | 0.140 |
Why?
| | M Phase Cell Cycle Checkpoints | 1 | 2016 | 23 | 0.140 |
Why?
| | Checkpoint Kinase 1 | 1 | 2016 | 28 | 0.140 |
Why?
| | Humans | 21 | 2022 | 114935 | 0.140 |
Why?
| | Cyclin-Dependent Kinase 6 | 2 | 2012 | 37 | 0.130 |
Why?
| | Mitosis | 1 | 2016 | 164 | 0.130 |
Why?
| | Mice | 13 | 2019 | 14935 | 0.130 |
Why?
| | MicroRNAs | 2 | 2012 | 601 | 0.130 |
Why?
| | Radiation, Ionizing | 2 | 2012 | 72 | 0.120 |
Why?
| | Longevity | 3 | 2011 | 137 | 0.120 |
Why?
| | HeLa Cells | 1 | 2016 | 562 | 0.120 |
Why?
| | Central Nervous System Neoplasms | 2 | 2012 | 126 | 0.110 |
Why?
| | Histones | 2 | 2020 | 536 | 0.110 |
Why?
| | Mammary Neoplasms, Experimental | 2 | 2003 | 64 | 0.100 |
Why?
| | Colony-Forming Units Assay | 1 | 2012 | 89 | 0.100 |
Why?
| | Immunoenzyme Techniques | 1 | 2012 | 195 | 0.100 |
Why?
| | Colorado | 1 | 2022 | 4091 | 0.100 |
Why?
| | Melatonin | 2 | 2003 | 105 | 0.100 |
Why?
| | Gene Expression Profiling | 3 | 2014 | 1523 | 0.100 |
Why?
| | Luciferases | 1 | 2012 | 142 | 0.100 |
Why?
| | DNA Copy Number Variations | 1 | 2012 | 159 | 0.100 |
Why?
| | Child | 6 | 2022 | 18366 | 0.100 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2011 | 165 | 0.090 |
Why?
| | Oligopeptides | 2 | 2003 | 235 | 0.090 |
Why?
| | Repressor Proteins | 2 | 2012 | 368 | 0.090 |
Why?
| | Drug Design | 1 | 2011 | 151 | 0.090 |
Why?
| | Adenosine | 1 | 2012 | 202 | 0.090 |
Why?
| | Animals | 13 | 2019 | 31837 | 0.090 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2011 | 198 | 0.090 |
Why?
| | Intracellular Space | 1 | 2010 | 68 | 0.090 |
Why?
| | Receptors, Retinoic Acid | 1 | 2009 | 50 | 0.080 |
Why?
| | Neoplasm Proteins | 1 | 2012 | 385 | 0.080 |
Why?
| | Tretinoin | 1 | 2009 | 125 | 0.080 |
Why?
| | Cyclin-Dependent Kinases | 1 | 2009 | 111 | 0.080 |
Why?
| | Flow Cytometry | 1 | 2012 | 1087 | 0.080 |
Why?
| | Enzyme Inhibitors | 4 | 2012 | 752 | 0.080 |
Why?
| | Brain Neoplasms | 1 | 2016 | 987 | 0.080 |
Why?
| | DNA Methylation | 1 | 2012 | 496 | 0.080 |
Why?
| | Cell Survival | 3 | 2016 | 1022 | 0.070 |
Why?
| | Reactive Oxygen Species | 1 | 2010 | 536 | 0.070 |
Why?
| | Receptors, Estrogen | 1 | 2009 | 372 | 0.070 |
Why?
| | Piperazines | 2 | 2022 | 313 | 0.060 |
Why?
| | Case-Control Studies | 1 | 2012 | 3008 | 0.060 |
Why?
| | Signal Transduction | 4 | 2012 | 4524 | 0.060 |
Why?
| | Adolescent | 2 | 2012 | 17829 | 0.060 |
Why?
| | Child, Preschool | 5 | 2020 | 9086 | 0.060 |
Why?
| | Female | 11 | 2020 | 59580 | 0.060 |
Why?
| | Delta Sleep-Inducing Peptide | 1 | 2003 | 1 | 0.060 |
Why?
| | Genes, erbB-2 | 1 | 2003 | 26 | 0.050 |
Why?
| | G2 Phase Cell Cycle Checkpoints | 1 | 2022 | 41 | 0.050 |
Why?
| | Neoplasms, Experimental | 1 | 2003 | 152 | 0.050 |
Why?
| | Ovary | 1 | 2003 | 191 | 0.050 |
Why?
| | Neural Stem Cells | 2 | 2012 | 115 | 0.050 |
Why?
| | Carcinoma | 1 | 2003 | 199 | 0.050 |
Why?
| | Epigenomics | 1 | 2020 | 102 | 0.040 |
Why?
| | Pyrimidines | 2 | 2014 | 378 | 0.040 |
Why?
| | Astrocytoma | 1 | 2020 | 109 | 0.040 |
Why?
| | Brain Stem Neoplasms | 1 | 2020 | 86 | 0.040 |
Why?
| | Antioxidants | 1 | 2003 | 530 | 0.040 |
Why?
| | Pyridines | 2 | 2012 | 425 | 0.040 |
Why?
| | Lysine | 1 | 2020 | 242 | 0.040 |
Why?
| | Body Weight | 4 | 2003 | 868 | 0.040 |
Why?
| | Prognosis | 2 | 2016 | 3344 | 0.040 |
Why?
| | Benzodiazepinones | 1 | 2016 | 14 | 0.030 |
Why?
| | Genes, myc | 1 | 2016 | 47 | 0.030 |
Why?
| | Adenocarcinoma | 1 | 2003 | 801 | 0.030 |
Why?
| | Urea | 1 | 2016 | 68 | 0.030 |
Why?
| | Biomarkers | 2 | 2003 | 3418 | 0.030 |
Why?
| | Thiophenes | 1 | 2016 | 108 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2020 | 863 | 0.030 |
Why?
| | Cisplatin | 1 | 2016 | 263 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2016 | 623 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2012 | 1856 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 817 | 0.030 |
Why?
| | DNA Damage | 1 | 2016 | 357 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2016 | 729 | 0.030 |
Why?
| | Mice, Transgenic | 3 | 2003 | 1953 | 0.030 |
Why?
| | Pyrimidinones | 1 | 2014 | 88 | 0.030 |
Why?
| | Up-Regulation | 1 | 2016 | 812 | 0.030 |
Why?
| | Estrus | 2 | 2003 | 11 | 0.030 |
Why?
| | Cathepsin B | 1 | 2012 | 14 | 0.030 |
Why?
| | Rapamycin-Insensitive Companion of mTOR Protein | 1 | 2012 | 28 | 0.030 |
Why?
| | Argonaute Proteins | 1 | 2012 | 28 | 0.030 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2012 | 128 | 0.030 |
Why?
| | Homozygote | 2 | 2003 | 188 | 0.030 |
Why?
| | Chromosome Aberrations | 2 | 2003 | 138 | 0.030 |
Why?
| | Mice, Inbred Strains | 2 | 2003 | 398 | 0.030 |
Why?
| | Body Temperature | 2 | 2003 | 208 | 0.030 |
Why?
| | 3' Untranslated Regions | 1 | 2012 | 129 | 0.030 |
Why?
| | Aurora Kinases | 1 | 2012 | 28 | 0.030 |
Why?
| | Genome, Human | 1 | 2014 | 352 | 0.020 |
Why?
| | Microarray Analysis | 1 | 2012 | 119 | 0.020 |
Why?
| | Aurora Kinase A | 1 | 2012 | 52 | 0.020 |
Why?
| | Tubulin | 1 | 2012 | 123 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2012 | 445 | 0.020 |
Why?
| | Anticarcinogenic Agents | 1 | 2011 | 67 | 0.020 |
Why?
| | Acetylation | 1 | 2011 | 211 | 0.020 |
Why?
| | Benzamides | 1 | 2011 | 169 | 0.020 |
Why?
| | RNA Interference | 1 | 2012 | 437 | 0.020 |
Why?
| | Eating | 2 | 2003 | 347 | 0.020 |
Why?
| | Mutation | 1 | 2020 | 3353 | 0.020 |
Why?
| | Survival Rate | 1 | 2014 | 1644 | 0.020 |
Why?
| | Retinoic Acid Receptor alpha | 1 | 2009 | 11 | 0.020 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2012 | 441 | 0.020 |
Why?
| | Electrophoretic Mobility Shift Assay | 1 | 2009 | 73 | 0.020 |
Why?
| | Superoxides | 1 | 2010 | 214 | 0.020 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2009 | 129 | 0.020 |
Why?
| | Neoplasms | 1 | 2003 | 2106 | 0.020 |
Why?
| | Genomics | 1 | 2014 | 641 | 0.020 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2009 | 88 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2011 | 1126 | 0.020 |
Why?
| | Carrier Proteins | 1 | 2012 | 696 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 1361 | 0.020 |
Why?
| | Cell Movement | 1 | 2012 | 867 | 0.020 |
Why?
| | Protein Kinase Inhibitors | 1 | 2014 | 796 | 0.020 |
Why?
| | Caspases | 1 | 2009 | 245 | 0.020 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2009 | 175 | 0.020 |
Why?
| | Down-Regulation | 1 | 2010 | 596 | 0.020 |
Why?
| | Feeding Behavior | 2 | 2003 | 572 | 0.020 |
Why?
| | Incidence | 2 | 2003 | 2316 | 0.020 |
Why?
| | Base Sequence | 1 | 2010 | 2118 | 0.020 |
Why?
| | Male | 3 | 2020 | 55663 | 0.020 |
Why?
| | RNA | 1 | 2012 | 810 | 0.020 |
Why?
| | Phosphorylation | 1 | 2009 | 1572 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2009 | 1133 | 0.020 |
Why?
| | Phenotype | 1 | 2012 | 2817 | 0.020 |
Why?
| | Protein Binding | 1 | 2009 | 1897 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 2009 | 1317 | 0.010 |
Why?
| | Rats | 1 | 2011 | 4963 | 0.010 |
Why?
| | Estrous Cycle | 1 | 2003 | 14 | 0.010 |
Why?
| | Photoperiod | 1 | 2003 | 48 | 0.010 |
Why?
| | Pregnancy, Animal | 1 | 2003 | 52 | 0.010 |
Why?
| | Ovariectomy | 1 | 2003 | 116 | 0.010 |
Why?
| | Life Expectancy | 1 | 2003 | 51 | 0.010 |
Why?
| | Dipeptides | 1 | 2002 | 48 | 0.010 |
Why?
| | Time Factors | 2 | 2003 | 6125 | 0.010 |
Why?
| | Polycystic Kidney Diseases | 1 | 2003 | 55 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2011 | 3549 | 0.010 |
Why?
| | Random Allocation | 1 | 2003 | 335 | 0.010 |
Why?
| | Cohort Studies | 1 | 2012 | 4903 | 0.010 |
Why?
| | Bone Marrow Cells | 1 | 2003 | 267 | 0.010 |
Why?
| | Leukemia | 1 | 2003 | 210 | 0.010 |
Why?
| | Cell Division | 1 | 2002 | 759 | 0.010 |
Why?
| | Survival Analysis | 1 | 2003 | 1220 | 0.010 |
Why?
| | Models, Statistical | 1 | 2003 | 604 | 0.010 |
Why?
| | Models, Theoretical | 1 | 2003 | 516 | 0.010 |
Why?
| | Brain | 1 | 2010 | 2372 | 0.010 |
Why?
| | Age Factors | 1 | 2003 | 2891 | 0.010 |
Why?
| | Disease Progression | 1 | 2003 | 2392 | 0.010 |
Why?
| | Pregnancy | 1 | 2003 | 5527 | 0.010 |
Why?
| | Risk Factors | 1 | 2003 | 8637 | 0.010 |
Why?
| | Lung Neoplasms | 1 | 2002 | 2223 | 0.010 |
Why?
|
|
Alimova's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|